Moreover, in recent studies, the presence of p53 aggregation affected the response of ovarian cancer cells to chemotherapy, which agrees with earlier studies that showed an association between chemoresistance and the presence of shorter p53 isoforms.[23,42] These results strongly suggest a more robust relationship between p53 isoforms and aggregation. This evidence concerns the gene TP53 and ovarian cancer.